Article Text

PDF

Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE
  1. Chris Parker1,2
  1. 1 The Royal Marsden NHS Foundation Trust, Sutton, UK
  2. 2 The Institute of Cancer Research, Sutton, UK
  1. Correspondence to Dr Chris Parker; chris.parker{at}rmh.nhs.uk
  • podcast

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0

Statistics from Altmetric.com

Radiotherapy to the primary tumour has been much discussed as a possible intervention in patients with newly diagnosed metastatic prostate cancer. Results of the STAMPEDE trial indicate that overall no survival advantage can be achieved by the addition of radiotherapy. However, patients with low volume, oligometastatic disease were shown to benefit in a predefined subgroup analysis. In the current podcast Dr. Parker provides insight on the practice changing impact of the STAMPEDE trial and gives an outlook what is next on the horizon in metastatic prostate cancer therapy.

View Abstract

Footnotes

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.